Caribou Biosciences (CRBU) Receivables - Net (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Receivables - Net of $227000.0 for Q1 2026, up 157.95% year-over-year from $88000.0 in Q1 2025, and up 228.99% quarter-over-quarter from $69000.0 in Q4 2025.
Caribou Biosciences (CRBU) Receivables - Net (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Receivables - Net for 7 consecutive years, with $227000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 157.95% year-over-year to $227000.0; the TTM figure through Mar 2026 stood at $227000.0 (up 157.95% YoY), while the FY2025 annual figure was $69000.0, down 73.96% from the prior year.
- Receivables - Net climbed to $227000.0 in Q1 2026 per CRBU's latest filing, from $69000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $1.5 million in Q1 2023 and bottomed at $69000.0 in Q4 2025.
- Historically, Receivables - Net has averaged $432647.1 across 5 years, with a median of $242000.0 in 2025.
- Annual changes were most pronounced in 2022 — Receivables - Net surged 26100.0% — and 2025, when it slumped 90.4%.
- Caribou Biosciences' Receivables - Net stood at $202000.0 in 2022, then dropped by 26.73% to $148000.0 in 2023, then jumped by 79.05% to $265000.0 in 2024, then tumbled by 73.96% to $69000.0 in 2025, then soared by 228.99% to $227000.0 in 2026.
- Business Quant data shows CRBU's Receivables - Net at $227000.0 in Q1 2026, $69000.0 in Q4 2025, and $242000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Caribou Biosciences | 163.09 Mn | 50.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 203,000.00 |
| Jun 30, 2026 | 203,000.00 |
| Mar 31, 2026 | 227,000.00 |
| Mar 31, 2026 | 227,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Sep 30, 2025 | 242,000.00 |
| Sep 30, 2025 | 242,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | 265,000.00 |
| Dec 31, 2024 | 265,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 215,000.00 |
| Jun 30, 2024 | 215,000.00 |
| Mar 31, 2024 | 917,000.00 |
| Mar 31, 2024 | 917,000.00 |